How Long Do Glass-Skin Treatments Last in Seoul?

When you compare glass-skin or skin-boosting options in Gangnam, the treatment family matters more than the clinic’s name. Published trial data show hyaluronic acid microinjections losing effect on a measurable monthly curve, while Rejuran Healer (PN) and the Juvelook family (PDLLA) are harder to pin to one retention number because the underlying studies vary in quality and injection technique, and exosome treatments have no FDA-approved product to compare against at all. Here is what that evidence says, family by family, and what to confirm before you rebook.

Hello, I’m Dr. Kim Yeonjin, director of UH CELL Clinic’s Gangnam branch. “Which clinic gives the best glass-skin or glow results in 2026?” is a question I hear often, and the honest answer is conditional. The same treatment name can mean different products, used on different skin conditions, on different schedules, and the result and its duration change accordingly. Knowing the evidence behind each family before you walk into a consultation lets you ask sharper questions once you’re there.

I covered how ingredient choice changes results in a separate piece on HA boosters versus PN injections. This article focuses on retention and rebooking timing.

What “Glass Skin” Actually Describes

The look people call glass skin is smooth, well-hydrated texture that reflects light evenly rather than any single procedure. That’s why skin boosters, which add moisture-binding ingredients to the dermis or shift the skin’s regeneration environment, come up most often in these conversations. When the FDA approved Skinvive in 2023, the indication it granted was specifically smoothness of the cheek skin, and the US aesthetics outlet ModernAesthetics described the product as improving skin quality by smoothing and hydrating rather than filling a specific area the way a standard filler does.

If sagging along the jawline or cheeks is the main concern instead, the consultation shifts toward energy-based lifting devices such as Ultherapy and Thermage, which target different tissue layers. I compared those two devices directly in a separate article on choosing between them.

At our Gangnam branch, we diagnose the individual skin condition before naming a treatment. Whether the issue is rough texture, dryness, lost elasticity, or sagging (or some combination) changes which family of treatment is even a reasonable candidate.

Four Families, Four Levels of Evidence

The table below carries the published evidence for each family as reported. The studies differ in design and population, so the rows should not be read as a head-to-head ranking.

Family (example products)	Primary target	Form of published evidence	What can be said about duration	What to confirm when scheduling
HA microinjection (Skinvive, similar boosters)	Cheek skin smoothness and hydration	Randomized, multicenter, evaluator-blinded trial (Skinvive)	More than half of participants still showed at least one grade of improvement at 6 months in that trial	Injection-site redness, swelling, bruising, small bumps
PN (Rejuran Healer)	Texture, elasticity, fine lines	Systematic review: 9 studies, 219 patients, quality rated low to moderate	Technique and injection site vary too much across studies for a standard duration figure	Side effects reported as generally mild and temporary
PDLLA + uncrosslinked HA (Juvelook family)	Texture and elasticity via collagen stimulation	Preliminary Korean-population study, short follow-up	Evidence is insufficient to establish long-term retention	Particle size differs by product name; site selection matters
Exosomes	Claims of improved regeneration	No FDA-approved product exists	No published retention figures comparable to the families above	Exact product name, whether it’s injected or applied, and its approval status

HA Microinjection: The Family With a Month-by-Month Curve

Of the four families, this one has public data that tracks duration in monthly increments.

Allergan Aesthetics’ pivotal randomized, multicenter, evaluator-blinded trial, announced alongside the 2023 FDA approval, found that 58% of participants (73 of 125) gained at least one grade on the cheek smoothness scale (ACSS) at 1 month, and 56% (69 of 124) still showed that improvement at 6 months, according to ModernAesthetics’ coverage. The medical outlet HCPLive reported from the same trial that satisfaction with skin radiance rose from 11% before treatment to 63% at the 6-month mark.

Volite, Allergan’s related HA microinjection product approved earlier in Europe, has longer follow-up data. A European post-marketing study registered on ClinicalTrials.gov followed 131 patients in a single-arm design and recorded ACSS response rates of 96.2% at 1 month, 76.3% at 4 months, 34.9% at 6 months, and 15.8% at 9 months, before climbing back to 87.1% one month after a touch-up session.

The two studies used different designs and can’t be compared number for number. Both point the same direction, though: effect fades over time and a touch-up brings it back up. These figures describe specific products, not HA microinjections as a category, so they shouldn’t be assumed to apply to every brand sold under a similar name.

HCPLive also reported that most participants in the pivotal trial experienced injection-site reactions, including redness, swelling, bruising, small bumps, tenderness, and itching. If you’re visiting on a short trip, that’s worth weighing when you pick a treatment date.

PN and PDLLA: Why a Single Retention Number Isn’t Settled

A 2024 systematic review in the Journal of Cosmetic Dermatology, led by Smaragda Lampridou, pooled 9 studies and 219 patients on PN injections. Study quality was rated low to moderate, and injection site and technique varied across the pooled studies. The authors reported statistically significant improvements in wrinkles, texture, and elasticity across several of the studies, but concluded that there’s no consensus yet on an optimal protocol and called for more rigorous research.

So if you’re told Rejuran Healer “lasts several months,” it’s worth asking how many sessions, what interval, and which treatment area that figure is based on.

Juvelook products combine PDLLA particles with uncrosslinked HA. A 2024 preliminary study in the same journal examined this combination’s effect on skin regeneration, but the authors themselves flagged that the study enrolled only Korean participants, that outcome assessment lacked full objectivity, and that follow-up was short.

Products within this family also differ from each other. A 2025 case report in the same journal described Juvelook’s particle size as 20 to 30 micrometers versus 40 to 60 micrometers in Juvelook Volume, and discussed a case of nodule formation after Juvelook Volume was injected under the eye. That’s a reason to confirm both the exact product name and the injection site in consultation.

If You’re Offered an Exosome Treatment

The FDA issued a public safety notice in December 2019 after serious adverse events were reported in Nebraska patients treated with unapproved products marketed as containing exosomes. The FDA’s current consumer warning states that no FDA-approved exosome product exists.

That’s a US regulatory standard, and approval frameworks differ by country. If an exosome-based treatment comes up in your consultation, the questions worth asking are the product name, whether it’s injected or topical, and what approval it holds in the country where it’s offered. Within the material I reviewed for this piece, I didn’t find published retention figures for exosomes that could be set alongside the three families above.

Timing Your Departure and Your Next Visit

Because injectable families carry documented injection-site reactions, I generally recommend scheduling them earlier in your stay rather than right before you fly home. How much buffer you personally need varies, and we give a specific recommendation after diagnosis. For flight-timing guidance after a lifting procedure specifically, I covered symptom-based timing in a companion article on flying after Ultherapy.

For your next visit, the HA microinjection data above gives a reasonable reference point: the European post-marketing study showed response rates dropping sharply between 4 and 6 months. For that family, I suggest treating the 4-to-6-month window as a candidate for your next consultation. That window comes from a single product’s data rather than a proven retreatment rule, and it doesn’t transfer to the PN or PDLLA families.

Diagnosis and Recovery at Our Gangnam Location

Our Gangnam branch sits inside UH FLAT SIGNATURE Gangnam, at WD Building floors 2 and 3, Teheran-ro 8-gil 13. Because it operates as an on-site amenity of the UHC hotel group rather than a separately contracted clinic, the path from treatment room to guest room stays within one building. Treatments take place in private rooms.

UHC hotel guests may choose one complimentary service: either a 30-minute oxygen chamber session or a vitamin IV drip. Using both costs an additional KRW 55,000 for the IV. There’s no evidence that this benefit changes how a skin booster performs. What it does offer is a way to spend your recovery time without leaving the building.

Our Gangnam branch has Japanese, Chinese, and English-speaking interpreting staff on site. I completed graduate study at Seoul National University and trained at Seoul National University Hospital, and I serve as an Allergan (Juvederm, Botox) faculty member, a Potenza and Ultherapy Z Key Doctor, an instructor for the Korean Academy of Clinical Cosmetic Medicine, and a full member of the Korean Society for Aesthetic Plastic Surgery and Laser Medicine.

Check Points Before You Book

• Write down whether your main concern is texture and hydration, elasticity, or sagging.
• Confirm the exact product name of whatever’s recommended; particle size and intended use differ within the same family.
• Ask what session count, interval, and treatment area the quoted retention figure is based on.
• If exosomes come up, ask for the product name, delivery method, and approval status.
• Build in buffer time between your treatment date and your departure date.
• Set a tentative date for your next visit before you leave.

FAQ

Does one session keep glass skin results going?

In the European post-marketing study cited above, 31 of 131 patients (23.7%) received a touch-up session, and by 9 months 62 of 131 (47.3%) had been retreated. Even Skinvive’s 6-month retention figures in its own trial carried the qualifier “with optimal treatment.” Session count is set after diagnosis, based on skin condition and how often you’re able to return to Seoul.

Can darker skin tones or patients in their early 20s get these treatments?

According to ModernAesthetics’ coverage, Skinvive was approved in the US for adults 21 and older across all Fitzpatrick skin types I through VI. That reflects US approval scope specifically. Individual suitability is determined from skin condition and medical history.

Will the VAT refund for cosmetic procedures still apply in 2026?

Under the 2025 tax reform plan from Korea’s Ministry of Economy and Finance, the 10% VAT refund program for foreign tourists’ cosmetic medical services was set to end on December 31, 2025, as reported by Hit News (2025). Korea Economic Daily (2026) later reported that a bill to extend the program through the end of 2027 was referred to a National Assembly subcommittee in July 2026. I’d recommend confirming the program’s status again before you book your trip.

Send over your travel dates and skin concerns ahead of time, and we can map out a treatment family and schedule together once you’re here for your diagnosis. Full terms for the UHC hotel guest benefit are listed on our promotion page.

※ Skin response and recovery time vary by individual. Please consult a licensed physician for an accurate diagnosis and treatment plan.